Verona Pharma plc Verona Pharma Plc : Result Of General Meeting Of Shareholders

 
TIDMVRP 
 
 
   LONDON, June 26, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP.L), 
a clinical-stage biopharmaceutical company focused on developing and 
commercializing innovative therapeutics for the treatment of respiratory 
diseases, announces that all resolutions proposed at the General Meeting 
held today were duly passed on a poll, the results of which are set out 
below. 
 
 
 
 
                             % of votes     Votes     % of votes      Votes 
Resolution       Votes for      cast       against       cast         total 
1. Authority to 
 allot shares    86,113,803  94.70%       4,820,196    5.30%        90,933,999 
2. 
 Disapplication 
 of pre-emption 
 rights          86,117,638  94.66%       4,860,361    5.34%        90,977,999 
 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
clinical trials, treatment with RPL554 has shown clinically meaningful 
and statistically significant improvements in lung function and clinical 
symptoms as compared to placebo, and has shown statistically significant 
improvements in lung function when administered in addition to 
frequently used short- and long-acting bronchodilators as compared to 
such bronchodilators administered as a single agent. Verona Pharma is 
developing RPL554 for the treatment of chronic obstructive pulmonary 
disease (COPD), cystic fibrosis (CF), and potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/

(END) Dow Jones Newswires

June 26, 2018 12:22 ET (16:22 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024